Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia.

Trial Profile

The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Amantadine; Metformin; Zonisamide
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2008 Planned end date changed from 1 Dec 2008 to 1 Sep 2008 according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top